Real-world impact of transitioning from one lipoprotein(a) assay to another in a clinical setting
Transitioning from one Lp(a) immunoassay to another had significant impact on Lp(a) results, particularly in individuals approaching clinically relevant Lp(a) thresholds.
Authors
- Kjetil Retterstøl (ORCID: https://orcid.org/0000-0002-1309-7556)
- Erik Arnesen (ORCID: https://orcid.org/0000-0002-5568-8813)
- Kirsten B. Holven (ORCID: https://orcid.org/0000-0002-8674-9703)
- Thomas Olsén (ORCID: https://orcid.org/0000-0003-1805-5221)
- Jacob J. Christensen (ORCID: https://orcid.org/0000-0001-8008-0650)
- Børge Grønne Nordestgaard (ORCID: https://orcid.org/0000-0002-1954-7220)
- Janeni Jeevanathan
- Ying‐Yeh Chen (ORCID: https://orcid.org/0000-0001-5543-5704)
- Torleif Trydal
- Michael Sovershaev
- Sigrid Blom
Institutions
- University of Copenhagen (DK)
- Oslo University Hospital (NO)
- Statistics Norway (NO)
- University of Oslo (NO)
- Gentofte Hospital (DK)
- Hospital of Southern Norway (NO)
- Metropolitan University (BD)
- Novartis (Norway) (NO)
- Universidad Metropolitana (PR)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2024-08-25
- DOI
- https://doi.org/10.1016/j.ajpc.2024.100726
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- Universitetet i Oslo
- Norges Forskningsråd
- Novartis Pharma
- Medisinske fakultet, Universitetet i Oslo